Cyclic Dinucleotides as STING Agonists for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer treatment, particularly involving cytokine administration, are limited by the short half-life of cytokines in the blood, requiring frequent and high doses, and there is a need for more effective STING agonists that can induce therapeutic cytokines for enhanced antitumor efficacy.
Innovation Solution
Development of novel cyclic dinucleotides that act as STING agonists, including specific compounds of formula (I), which activate the STING receptor to induce Type I interferons and pro-inflammatory cytokines, offering a potential treatment for cancer by enhancing antitumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokines are administered as immunotherapy agents, then immune response is activated, but the short half-life in blood requires frequent and high doses
Solution Approach 1:
The patent uses STING agonists as intermediary molecules that do not directly provide immune activation but rather trigger the endogenous production of cytokines through STING pathway activation. This mediator approach allows sustained immune response without the short half-life limitation of direct cytokine administration.
Solution Approach 2:
The STING agonist therapy enables the patient's own immune system to produce cytokines endogenously through STING pathway activation, rather than relying on exogenous cytokine administration. This self-service mechanism sustains immune response longer as the body's own cells produce and secrete cytokines continuously.
2Reliability
If exogenous cytokines are administered for cancer treatment, then antitumor efficacy is achieved, but frequent and high doses are required due to short half-life
Solution Approach 1:
The STING agonist serves as an intermediary that triggers endogenous cytokine production, replacing the need for continuous exogenous cytokine administration. This mediator enables sustained antitumor efficacy with reduced dosing frequency and lower total drug amounts.
Solution Approach 2:
The therapy activates the patient's own cytokine production systems, allowing the body to sustain antitumor immune responses endogenously. This self-service approach eliminates the need for frequent high-dose exogenous administration while maintaining therapeutic efficacy.
3Reliability
If STING agonists are used to induce cytokine production, then therapeutic cytokines are generated, but the development of effective agonists with optimal properties is challenging
Solution Approach 1:
The patent modifies the chemical structure of cyclic dinucleotides by changing parameters such as substituting oxygen with sulfur atoms (forming cyclic dinucleotide sulfates) and modifying the nucleotide composition. These parameter changes optimize the agonist properties for enhanced STING activation and therapeutic efficacy.
Solution Approach 2:
The invention creates composite molecular structures by combining different nucleotide components and modifying existing cyclic dinucleotide frameworks. These composite structures (such as mixed phosphodiester bridge configurations and substituted nucleotides) achieve optimal balance between potency, stability, and pharmacokinetic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cyclic dinucleotides effectively induce cytokine production, providing enhanced antitumor immune efficacy and potentially improving treatment outcomes for cancer by activating the STING pathway, thereby overcoming the limitations of existing cytokine administration methods.
Implementation Method 1
The binding to STING by an agonist activates a signaling pathway culminating in the induction of Type I IFNs
Data Source
AI summary
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.